CEO / CFO / Director Resignations & Appointments | Oct 21, 2021
VividSeats post de-SPAC board is set as it began trading, plus all the other CEO, CFO and director moves.
No big name CEO or CFO moves over the past week — not like last week with KKR’s founders stepping aside — but plenty of moves to digest. VividSeats de-SPAC’d and their official post-merger board began its work. Read on for the full listing of CEO, CFO, and Director moves over the past week.
CEO / CFO Moves
Before joining the Company, Mr. Gray, age 52, served as the Chief Financial Officer at Superior Essex, a global manufacturer and distributor of communications cable, magnet winding wire and insulating enamels used in electric motors and transformers, since 2017. Prior to 2017, he served as Superior Essex’s Vice President and Corporate Controller from 2014 to 2017. From 2010 to 2013, he was the VP Finance and IT for Cooper Industries’ Bussman Division, a provider of critical circuit and power electronics protection, power management, and electrical safety. Mr. Gary also held various executive management positions at Digital Blue and Newell Brands. Mr. Gray holds a degree in accounting from Penn State, was certified as a CPA by the Maryland Board of Public Accountancy and received his CMA from the Institute of Management Accountants.
Prior to joining the Company, from May 2018 to April 2020, Mr. Golubieski, 56, served as Chief Financial Officer of IlluminOss Medical, Inc., a medical device company, prior to its acquisition by a private equity firm. From August 2017 to May 2018, Mr. Golubieski served as Chief Financial Officer of Axsome Therapeutics, Inc., a biopharmaceutical company. From June 2014 to August 2017, Mr. Golubieski served as Chief Financial Officer of Osmotica Holdings, LLC, a biopharmaceutical company. From July 2013 to June 2014, Mr. Golubieski served as Interim Chief Financial Officer of Lantheus Medical Imaging, Inc., a public medical diagnostic company, which he helped complete its initial public offering. Mr. Golubieski also served as Chief Financial Officer at Fougera Pharmaceuticals Inc., a pharmaceutical company, prior to its acquisiton by Sandoz, a division of Novartis, and as Senior Vice President, Financial Planning & Analysis at King Pharmaceuticals Inc., a pharmaceutical company, prior to its acquisition by Pfizer Inc. Mr. Golubieski also held roles of increasingly responsibility at Bristol-Myers Squibb Company and was a staff accountant at PricewaterouseCoopers. Mr. Golubieski received a MBA and a BS from Rider University.
Laurance Roberts has been our Chief Financial Officer and Treasurer since July 2013. From 2008 to 2012 he was Chief Operating Officer for KFC, a major fried chicken restaurant chain and a division of Yum Brands. In 2008, he was also General Manager for KFC Restaurant Operating Company. Before that, he spent three years as Chief Financial Officer of KFC, and three years as Chief Financial Officer of Yum Brands' Pizza Hut joint venture in the United Kingdom. Mr. Roberts holds an MBA from the University of Michigan and a bachelor's degree in economics from Bucknell University.
Matthew C. Moellering has served as our Executive Vice President, Chief Administrative Officer, Chief Financial Officer, Treasurer and Secretary since October 2009. Prior to that, he served as our Senior Vice President, Chief Financial Officer, Treasurer and Secretary from July 2007 to October 2009 and our Vice President of Finance from September 2006 to July 2007. Prior to that, he served in various roles with Limited Brands from February 2003 to September 2006, most recently as Vice President of Financial Planning. He started with Limited Brands as a Finance Director from 2003 until 2004. Prior to that, Mr. Moellering served in various roles with Procter and Gamble where he was employed from July 1995 until February 2003 and prior to that as an officer in the United States Army.
Mr. Samath will continue to serve in the capacity of Vice President and Corporate Controller. Mr. Samath, age 43, joined Intuitive in April 2013 as Vice President and Corporate Controller. Prior to joining Intuitive, Mr. Samath was the Vice President Finance and Corporate Controller at Atmel Corporation from October 2011 to April 2013 and served as its Principal Accounting Officer from December 2011 to April 2013. Prior to joining Atmel, Mr. Samath served in various finance roles at National Semiconductor Corporation (acquired by Texas Instruments Incorporated in September 2011) from February 1991 to September 2011. From June 2005 to June 2010, Mr. Samath was the Principal Accounting Officer and Corporate Controller for National Semiconductor and from June 2010 to September 2011, Vice President, Principal Accounting Officer and Corporate Controller for National Semiconductor. Mr. Samath received his B.A. in Business Studies from London Metropolitan University and is a Certified Public Accountant (inactive).
Mr. Terry joined Marriott Vacation Club International, a division of Marriott International, in 1996 as Manager, Financial Accounting and was quickly promoted to roles of increasing responsibility. He had oversight of various financial and business planning functions and then rotated into executive roles covering new product development, brand management and product supply management. Most notably, Mr. Terry led work associated with significant milestones in the company’s growth, including the spin-off of Marriott Vacations Worldwide from Marriott International in 2011. He also supported the $4 billion acquisition of ILG in 2018 through due diligence efforts as well as by leading integration efforts within the Finance & Accounting organizations across the two companies.
Robert Mehrabian is an Armenian-American materials scientist and the Chairman, President and Chief Executive Officer of Teledyne Technologies Incorporated (TDY). He returned to this position on October 15, 2021. He had assumed the position of Executive Chairman on January 1, 2019. Previously, he was Chairman, President and Chief Executive Officer of the company from 2000 to December 31, 2018 and President and Chief Executive Officer from 1999 to 2000. Mehrabian held various Senior Executive positions at Allegheny Teledyne Incorporated (ATI) starting in July 1997, prior to the spin-off of Teledyne Technologies Incorporated in November 1999. Previously he was President of Carnegie Mellon University from 1990 to 1997. He has served on the board of directors of several public companies, including Mellon Financial Corporation and its successor, Bank of New York Mellon Corporation (1994-2011) and PPG Industries, Inc. (1992-2014).
Mehrabian holds bachelor and Doctor of Science degrees from the Massachusetts Institute of Technology (MIT).
Know someone that would like the newsletter?
Prior to joining Abeona, Dr. Seshadri served in roles of increasing responsibility at Celgene Corporation, now a subsidiary of Bristol-Myers Squibb Company (BMS), where he focused on development and commercialization of novel therapies in hematology and oncology. Most recently, he led the team responsible for the launch of Breyanzi® (lisocabtagene maraleucel; liso-cel), an autologous CD19-directed chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphoma. Dr. Seshadri has more than 20 years of experience including academia and various senior and executive leadership roles in the life sciences industry overseeing product development, regulatory submissions, and commercialization for novel therapies including personalized, autologous cell and gene therapies.
Dr. Kwon currently serves as an Operating Partner of Lightstone Ventures. Prior to this, Dr. Kwon served in roles of increasing responsibility at Momenta Pharmaceuticals Inc. ("Momenta"), including Chief Financial and Business Officer from January 2020 to January 2021, Chief Business Officer from October 2018 to January 2020, Senior Vice President, Corporate Development and Strategy from August 2015 to October 2018 and Vice President, Corporate Development and Strategy from January 2011 to July 2015. Prior to joining Momenta, Dr. Kwon was Senior Director of Business Development at Biogen Idec, where he led corporate development activities, including evaluation of a variety of transactions. Dr. Kwon received his B.S. from the Massachusetts Institute of Technology in 1994 and his Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University in 1999.
Mr. Simon was appointed to the CPUC by Governor Arnold Schwarzenegger in February 2007, ending his term in December 2012. During his time as a CPUC commissioner, Mr. Simon served as Chair of the National Association of Regulatory Utility Commissioners (“NARUC”) Natural Gas Committee; Chair of the LNG Partnership between the Department of Energy and NARUC; founding member of the Call to Action National Gas Pipeline Safety Taskforce with the U.S. Department of Transportation; and member of the National Petroleum Council. Mr. Simon currently serves on the board of Charah Solutions, Inc. (NYSE: CHRA).
Prior to his CPUC appointment, Mr. Simon served as Appointments Secretary in the Office of the Governor, the first African American in California history to hold this post. He also served as Adjunct Professor of Law at Golden Gate University School of Law and the University of California Hastings College of the Law. Prior to public service, Mr. Simon was an in-house counsel and compliance officer with Bank of America, Wells Fargo, and the Robertson Stephens investment bank.
In 2013, Mr. Simon created TAS Strategies, serving as an attorney and consultant on utility, infrastructure, financial services, and broadband projects. He is a frequent public speaker, expert witness and panelist on energy, infrastructure, diversity, and inclusion.
In 2019, Mr. Simon was elected Chairman of the Board of Directors for the California African American Chamber of Commerce and elected to the University of San Francisco Board of Trustees. He currently serves on the North American Energy Standards Board Advisory Council and is a member of the National Bar Association, Energy Bar Association, The Saint Thomas More Society and the National Board of Directors for the American Association of Blacks in Energy.
Mr. Simon received a bachelor’s degree in Economics from the University of San Francisco (Distinguished Alumni) and a Juris Doctor from the U.C. Hastings College of the Law. He is an active member of the State Bar of California.
Ms. Morgan, age 43, has been the owner/manager of Douglass Morgan, LLC, a legal and consulting firm, since January 2021. She is the immediate past Chairwoman of the Nevada Gaming Control Board, having served in that position from January 2019 until November 2020. She was appointed to this role by Governor Steve Sisolak and is the first African-American to have served as Chair. Ms. Morgan was previously appointed to the Nevada Gaming Commission by Governor Brian Sandoval in April 2018. While serving as a Commissioner, Ms. Morgan also served as Director of External Affairs for AT&T Services, Inc. from September 2016 to January 2019 and was responsible for managing AT&T’s government and community affairs in Nevada. She previously served as the City Attorney for the City of North Las Vegas from May 2008 to August 2016 and was the first African-American City Attorney in the State of Nevada. Prior to her public service with the City of North Las Vegas, Ms. Morgan served as Litigation Attorney for MGM Mirage (now known as MGM Resorts) from 2005 to May 2008. Ms. Morgan previously served as an Athletic Commissioner on the Nevada State Athletic Commission and served on the Board of Directors for Jobs for Nevada’s Graduates.
Ms. Williams, 50, serves as Chief Financial Officer of Onegevity Health (acquired by Thorne HealthTech, Inc., in early 2021), a health intelligence company with a precision health and wellness platform, a position she has held since 2019. As CFO of Onegevity Health, she is instrumental in implementing product strategies and cultivating organizational culture change. Before joining Onegevity, she served as Vice President of Equity Derivatives Operations at Goldman Sachs, working there from 2014 to 2019. Prior to that, Ms. Williams served as Chief Operating Officer for Solaire Generation, Inc., a solar energy equipment company. Ms. Williams holds an M.B.A. from Stanford University and a B.S. in Mechanical Engineering from Harvard University.
Dr. O’Neill, age 56, currently serves as the chief medical officer and executive vice president of research & development at Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Prior to joining Sarepta in June 2018, Dr. O’Neill served as the senior vice president of late-stage clinical development at Biogen Inc. (NASDAQ: BIIB) from November 2016 to June 2018. At Biogen, Dr. O’Neill also served in numerous other roles after joining the company in April 2003, including as senior vice president of drug innovation units, vice president of MS franchise and head of multiple sclerosis research and development, vice president of global neurology clinical development, vice president of global late-stage clinical development, and vice president of experimental neurology (early stage). Dr. O’Neill is licensed to practice medicine in the state of Massachusetts. He is a member of the American Academy of Neurology and a board-certified neurologist (ABPN). Dr. O’Neill is formerly chief resident in neurology at the Massachusetts General Hospital (MGH). From 1997 to 2015, Dr. O’Neill served as a clinical instructor in neurology at Harvard Medical School. Dr. O’Neill currently serves on the board of directors of Unity Biotechnology, Inc. (NASDAQ: UBX), as well as the board of directors of the Massachusetts Biotechnology Council (MassBio). Dr. O’Neill received a Bachelor of Medicine degree from University College Dublin and a Master of Medical Sciences degree from Harvard University.
Ms. Schlogel is Managing Partner and Founder of Atwater Capital, a media and entertainment sector-focused investment firm with offices in Los Angeles, California and Seoul, South Korea. Prior to founding Atwater, Ms. Schlogel served as a senior executive at several leading companies, including as Chief Investment Officer of Roc Nation and was a member of KKR's private equity team, where she specialized in the media sector and launched the growth equity division. Ms. Schlogel began her career in the Leveraged Finance and Capital Markets groups at Goldman Sachs in London and Los Angeles. Ms. Schlogel serves as a director on a number of boards, including as the Chairperson of Epidemic Sound, a provider of royalty-free music, and LEONINE Studios, Germany's leading content production and distribution company.
Ms. Eusey is the Chief Executive Officer and President of Beacon Pointe Advisors, which she co-founded in 2002. Beacon Pointe Advisors is one of the largest Registered Investment Advisors specializing in full service financial planning, research driven investments that partners with institutions, retirement-sponsored plans and private clients. Ms. Eusey serves or has served on numerous boards including the Charles Schwab Advisor Council, the TD Ameritrade Advisory Council, CNBC’s Advisory Council, as well as Scratchworks, a financial technology accelerator that connects innovative tech companies with investment and wealth management luminaries to advance the digital transformation of the financial services industry.
Since September 2020, Elisabeth Leiderman, M.D. has served as Chief Financial Officer and Head of Corporate Development for Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, with its headquarters in Boston, Massachusetts and is listed on Nasdaq. Before joining Decibel, from January 2020 to August 2020, Dr. Leiderman served as Chief Business Officer for Complexa, Inc., a clinical stage biopharmaceutical company focused on life-threatening fibrosis and inflammatory diseases. Prior to Complexa, Dr. Leiderman was Senior Vice President, Head of Corporate Development at Fortress Biotech from November 2016 to November 2019. Earlier in her career from 2007 to 2016, Dr. Leiderman developed her transaction and capital markets expertise in the healthcare investment banking groups at Nomura, Credit Suisse, Jefferies and UBS. Dr. Leiderman began her career in medical affairs at AstraZeneca, where she analyzed product and industry trends related to the central nervous system. Dr. Leiderman earned an M.D. from the Sackler School of Medicine at Tel Aviv University, an MBA from The Wharton School at the University of Pennsylvania and a B.A. from The University of Pennsylvania.
Mr. Heller is a Partner who oversees the New York office at Canyon Partners and is a member of the firm’s Investment Committee. He is responsible for the firm’s investments in companies in a wide range of industries, including REITs, Retail, Financial Institutions, Technology and Consumer. He has significant experience in various asset classes including stressed and distressed corporate debt, real estate securities, equities, municipal fixed income and structured products.
On October 8, 2021, the Company’s Board of Directors appointed William Bloom as a member of the Board of Directors. Mr. Bloom recently retired from his position as Executive Vice President of Technology, Data & Analytics, Claims, and Operations at The Hartford and has spent most of his career as an executive in the insurance industry
Mr. Hu, age 59, most recently served as Investment Analyst and Vice President of Capital World Investors, an investment group in the Capital Group Companies, Inc., from 2003 to 2017. He previously served as Manager of Project Finance, Corporate Treasury at Unocal Corporation from 2002 to 2003, and as Global Energy Practice Consultant at McKinsey & Company from 2000 to 2002. Prior to joining McKinsey, Mr. Hu served in various roles at Atlantic Richfield Company (ARCO) from 1989 to 2000, including as Vice President Downstream Operations and Business Development from 1998 to 2000. Mr. Hu also currently serves as an advisory board member for the Geology & Planetary Science Division at the California Institute of Technology. Mr. Hu holds a Master of Business Administration Degree from The Amos Tuck School at Dartmouth College and Master of Science and Bachelor of Science Degrees in Engineering from Harvey Mudd College.
Mr. Simmons, 39, is an audit partner at WithumSmith+Brown, PC, a registered public accounting firm. Mr. Simmons' experience includes audit and consulting services regarding Sarbanes-Oxley 404 integrated audits, technical accounting and due diligence for domestic and international clients. Mr. Simmons is a past member of the National Association for Black Accountants and previously served on the Board of the New Jersey Technology Advisory Council. He is currently a member of the Association for Corporate Growth.
Donald W. Washington most recently served as the 11th Director of the United States Marshals Service (“USMS”). He previously served as a member of the board of directors for Home Bancorp, Inc. and Home Bank, N.A. from June 2016 until he was sworn in as director of USMS on March 29, 2019. He is a former partner in the law firm of Jones Walker LLP. His practice encompassed complex civil and criminal litigation and the representation of corporations and individuals in internal and government investigations. Washington served on the boards of the Innocence Project of New Orleans, Public Affairs Research Council of Louisiana, University of Louisiana Foundation, Community Foundation of Acadiana, Pines to the Gulf Girl Scout Council, and Goodwill Industries of Acadiana. Washington
received his juris doctor degree from South Texas College of Law, and his bachelor’s degree in Mechanical Engineering from the United States Military Academy at West Point.
John Hohneker, MD, has more than 30 years of experience as an executive in the biopharmaceutical industry and he now serves as a member of the Board for five other biotechnology companies including: BioTheryX, Inc. (private); Cygnal Therapeutics, Inc. (private); Aravive, Inc. (NASDAQ: ARAV); Evelo Biosciences (NASDAQ: EVLO); and Trishula Therapeutics (private). As an executive he has advanced several programs from pre-clinical evaluation through Phase IV, including products in oncology and immunology. He played a critical role in the development and commercialization of many blockbuster products including Cosentyx®, Gleevec®, Zometa®, Tasigna®, and Afinitor®. His experience includes 15 years at Novartis AG, from 2001 to 2015, where he was most recently Senior Vice President and Global Head of Development, Immunology and Dermatology. Prior to Novartis, he held several positions of increasing responsibility over a nearly 11-year period beginning at Burroughs Wellcome and then with its successor Glaxo Wellcome. Dr. Hohneker received a bachelor’s degree in chemistry from Gettysburg College and a medical degree from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School. He completed his internship and residency in internal medicine and his fellowship in medical oncology, all at the University of North Carolina at Chapel Hill. In addition to his operational experience, Dr. Hohneker has direct experience leading business development and licensing deals, raising capital, and serving on corporate boards through acquisitions.
Kevin Xie, PhD, has nearly twenty years of experience evaluating and investing in companies across an array of healthcare-related industries, first for 13 years on the buy-side and then for six years in industry where he also demonstrated the ability to add value through operational improvements. He is the Chief Financial Officer of Gracell Biotechnologies (Nasdaq: GRCL), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies intended to disrupt conventional approaches to CAR-T cell therapies. As CFO at Gracell since July 2020, Dr. Xie has completed a cross-over round and IPO that raised $340 million. Prior to Gracell, as President of Healthcare Holdings for Fosun Group, he built and managed a team of 20 investment professionals, which invested more than $2 billion in 30+ projects in biotechnology, pharmaceutical, healthcare information technology, and healthcare services industries. Dr. Xie co-founded and served as Portfolio Manager of Locust Walk Capital. Dr. Xie had previously served as Healthcare Sector Head at Scopia Capital, and as a Managing Director at Great Point Partners. He currently serves on the Board of Directors for ViewRay (Nasdaq: VRAY). Dr. Xie has a Bachelor of Science in Material Science and Engineering from Tianjin University, an MBA in Finance from The Wharton School of the University of Pennsylvania, and a PhD in Chemistry from The City University of New York.
Since July 2021, Dr. Borio has been a venture partner at ARCH Venture Partners, where she advises on new investment opportunities related to biologics manufacturing, clinical trials, novel therapies, and areas with large unmet clinical needs . She previously served as Senior Vice President of In-Q-Tel, an independent strategic investment firm that supports the mission of the United States national security community, from 2019 to 2020, and served as a member of the President's Transition COVID-19 Advisory Board. Previously, Dr. Borio served as Director, Medical and Biodefense Preparedness Policy, for the National Security Council from 2017 to 2019. Prior to that, Dr. Borio spent nearly 10 years at the United States Food and Drug Administration in roles of increasing responsibility, including Acting Chief Scientist and Assistant Commissioner for Counterterrorism Policy. Dr. Borio earned a B.S. in Zoology from George Washington University and an M.D. from George Washington University School of Medicine.
Mr. Myers has served as the chief executive officer of MediPrint Opthalmics, Inc. (formerly Leo Lens Pharma), a private eye-care company, since April 2020. Previously, Mr. Myers co-founded Alimera Sciences, Inc. (“Alimera”), a publicly traded pharmaceutical company, and served as its chief executive officer from 2003 until January 2019. Before co-founding Alimera, Mr. Myers was an initial employee of Novartis Ophthalmics (formerly CIBA Vision Ophthalmics), a pharmaceutical company, and served as its vice president of sales and marketing from 1991 to 1997 and as president from 1997 to 2003. Mr. Myers has served as a director of Alimera since 2003 and has served as chairman of its board of directors since January 2019. In addition, Mr. Myers served on the board of directors of Ocular Therapeutix, Inc., a publicly traded biopharmaceutical company, from 2009 to 2012. Mr. Myers holds a B.S. in Industrial Management from the Georgia Institute of Technology.
Ms. Davis has served as the Vice President and President - New Power Business of Cummins Inc. (“Cummins”) since July 2020. Prior to her current role, she served as Vice President of the global Filtration business, and served on the Board of Directors for two sizeable Cummins joint ventures; Shanghai Fleetguard in Shanghai, China and Fleetguard Filtrum LTD in Pune, India. Prior to that, Ms. Davis was President of the Cummins Northeast distributor as an owner, where she transformed a small business into a high-growth, customer-driven operation, achieving significant revenue and profit increases. Ms. Davis spent the early years of her career moving through a variety of global sales, strategy, and general management roles at AT&T, NCR and Cummins. She has lived in multiple U.S. cities and in Europe. Ms. Davis holds a Bachelor of Arts degree in English from Northwestern University and completed the Executive Program for Marketing Strategy at the University of Chicago Booth School of Business.
Mr. Malone has served as the Vice President and President – Filtration Group of Parker-Hannifin Corporation (“Parker”) since December 2014. Mr. Malone joined Parker in 2013 serving as Vice President of Operations for the Filtration Group where he was responsible for five of the group's divisions and the group sponsor for four of the seven global filtration platforms. Prior to Parker, Mr. Malone served as President and CEO for Purolator Filters with responsibility for the engineering, manufacturing, marketing, and sales of branded and private label filters to North American OEM and aftermarket customers. Prior to Purolator Filters, Mr. Malone held senior leadership positions with ArvinMeritor Light Vehicle Aftermarket and Arvin-Kayaba, LLC. Mr. Malone holds a Bachelor of Science degree in Industrial Engineering from Purdue University and a joint Master of Business Administration and Engineering from Northwestern University's Kellogg School of Management.
Harry C. Curtis was previously the Managing Director of Nomura Instinet, where he focused on gaming, lodging, and cruise industry research, from 2010 through 2020. In his approximately 30 years in equity research, during which he developed a wide following, he cultivated a deep knowledge of the cruise industry, the ability to identify investor sentiment and a comprehensive understanding of key drivers of Norwegian Cruise Line Holdings Ltd.’s business model. He has been recognized by institutional investors for his financial expertise and innovation in equity research. He also made frequent guest appearances and served as a media resource for organizations such as CNBC, Barron’s and the Wall Street Journal. Prior to that, he served as Managing Director, Chilton Investment Co. from 2008 through 2010, Managing Director, JP Morgan from 2002 through 2008, Visiting Professor, University of Nevada from 2002 through 2007, Partner/Managing Director, Robertson Stephens from 1998 through 2002, Vice President, Equity Research, Smith Barney from 1995 through 1997 and Vice President, Equity Research, Hanifen Imhoff from 1992 through 1995. He received a B.A. in English from Connecticut College and has been a Chartered Financial Analyst since 1991.
Samant has over 30 years of technology, product development and services experience, and currently serves as President and Chief Executive Officer of GlobalLogic Inc., a Hitachi Group Company. Prior to joining GlobalLogic, Samant was President of Ness Technologies, an IT services company, where he founded and built their product engineering services business. Prior roles include leading professional services for Hewlett-Packard’s Verifone business and establishing IBM’s first India-based engineering lab, globalizing the company’s R&D and software engineering efforts. Samant holds a bachelor’s degree in Computer Science and Engineering from University of Pune, India. Samant currently serves on the Board of Directors of Office Depot, since 2020.
Mr. Clarke served as Chief Executive Officer, President and a member of the Board of Directors of Navistar International Corp. (“Navistar”), a leading manufacturer and solutions provider for the medium- and heavy-duty truck segment, from April 2013 through July 2020 and then served as Executive Chairman from July 2020 through July 2021. He was Chairman of the Board from February 2017 through July 2021. Prior to his position as Chief Executive Officer and President, Mr. Clarke served as President and Chief Operating Officer of Navistar from August 2012 to April 2013, President of the Truck and Engine Group of Navistar from June 2012 to August 2012, President of Asia-Pacific Operations of Navistar, Inc. from 2011 to 2012 and as Senior Vice President of Strategic Initiatives from 2010 to 2011. Prior to joining Navistar, Mr. Clarke held various positions at General Motors Company, including President of General Motors North America from 2006 to 2009 and President of General Motors Asia Pacific from 2003 to 2006. He holds a B.S. in Mechanical Engineering from Kettering University, formerly the General Motors Institute, and an M.B.A. from the University of Michigan.
Sterling is the former Executive Vice President of Human Resources and Chief Human Resources Officer for Qualcomm, the world’s leading wireless communications technology company. Throughout her 25-year tenure with the company, Sterling led Qualcomm’s 33,000 employees through complex business transactions including acquisitions, joint ventures and divestitures, large-scale integration planning and significant international growth.
Sterling was also a member of Qualcomm’s executive committee working closely with its Board of Directors, and currently serves on the Board of Directors, Governance and Compensation and Human Capital Committees for Digital Turbine (NASDAQ: APPS), an application and content delivery platform.
Ms. Lo brings over two decades of combined agriculture, technology, and business experience to urban-gro. From May 2020 to May 2021, Ms. Lo was CEO of Sensei Ag Holdings, Inc. During her tenure, she led the building of four farms across North America, ranging from low-tech aquaponics and high dome poly, to high-tech glasshouse facilities. From April 2013 to April 2020, Ms. Lo was CEO of Crop One Holdings, Inc., a vertical farming company that owns FreshBoxFarms in Millis, MA. She is the first woman to serve as CEO of a major vertical farming company. Ms. Lo has a Bachelor’s degree in Political Science & Mathematics from Stanford University and an MBA from Harvard Business School.
Since January 2020, Ms. Masino has served as the President, International of Taco Bell, a subsidiary of Yum! Brands (NYSE: YUM). In this role, she drives all aspects of marketing, technology, product development, franchise management and corporate operations. Ms. Masino served as President, North America of Taco Bell from January 2018 to December 2019. Ms. Masino held senior positions at Mattel (NASDAQ: MAT) from April 2017 to January 2018 and at Sprinkles Cupcakes from 2014 to 2017. Ms. Masino serves on the board of PhysicianOne Urgent Care. Ms. Masino received her B.A from Miami University.
Mr. Chia joined Vivid Seats as Chief Executive Officer in November 2018. In this role, Mr. Chia leads the efforts to further elevate Vivid Seats and its offerings to consumers and sellers of tickets, building on Vivid Seats’ success as a leading marketplace with industry-pacing technology, track record of innovation and world-class experience for buying and selling live event tickets. Prior to joining Vivid Seats, Mr. Chia served as Chief Operating Officer from April 2015 to November 2018 at Grubhub Inc., an online and mobile food ordering and delivery marketplace. He has also held senior roles at Amazon.com, Inc., Cisco Systems, Inc., and General Electric Company, where he led strategic businesses and organizations. He also serves on the Board of Directors of 1871, as a member of the nominating and governance committee, and on the President’s advisory board of the Georgia Institute of Technology. Mr. Chia received his bachelor’s degree in Industrial Engineering from the Georgia Institute of Technology and his master of business administration degree from Emory University. Mr. Chia also served in the Singapore Armed Forces as an Armored Infantry Platoon Commander.
Mr. Donnini joined GTCR in 1991 and is currently a Managing Director, where he leads GTCR’s business services efforts. Prior to joining GTCR, Mr. Donnini worked at Bain & Company. Mr. Donnini is currently a director of AssuredPartners, Consumer Cellular, Park Place Technologies and Sotera (NYSE: SHC), where he serves on the Nomination and Corporate Governance Committee. Mr. Donnini previously served as a director of more than thirty previous GTCR investments. Mr. Donnini received his B.A. from Yale University and his M.B.A. from Stanford Graduate School of Business.
Mr. Ehrhart joined GTCR in 2012 and is currently a Director. Prior to joining GTCR, Mr. Ehrhart worked as an Analyst in the Financial Institutions group at Credit Suisse. Mr. Ehrhart serves on the Board of Directors of AssuredPartners and Consumer Cellular. He was previously a director of GreatCall and Park Place Technologies. Mr. Ehrhart received his B.A. from Georgetown University.
Mr. Dixon is the Co-Founder and Co-Chief Executive Officer of The St. James, a leading developer and operator of premium performance, wellness and lifestyle brands, technology experiences and destinations. From 2006 to 2013, Mr. Dixon was Senior Counsel and Assistant Corporate Secretary at Smithfield Foods, a global food business, where he focused on mergers and acquisitions and corporate governance and served as general counsel to multiple operating business units. Mr. Dixon began his legal career at McGuireWoods LLP and Cooley LLP, and as a Law Clerk to the Honorable James R. Spencer, United States District Court for the Eastern District of Virginia. He is a member of the Board of Trustees of Episcopal High School. Mr. Dixon received his B.B.A. from the College of William & Mary and his J.D. from William & Mary School of Law.
Mr. Anderson joined GTCR in 2000 and is currently a Managing Director. He previously worked at Bowles Hollowell Conner & Co. Mr. Anderson has served as a Director of Gogo Inc. (NASDAQ: GOGO) since March 2021, and also currently serves as a Director of CommerceHub and Jet Support Services Inc. In addition, Mr. Anderson was previously at Beeline, CAMP Systems, Cision, Global Traffic Network, Land Lease Group, Lytx and Landmark Aviation. Mr. Anderson received his B.A from the University of Virginia and his M.B.A from Harvard Business School.
Mr. Taylor has been an Operating Managing Director at Vista Equity Partners since 2006. In this role, he works with the leadership teams in the Vista portfolio creating value. Prior to joining Vista, Mr. Taylor spent over 13 years at Microsoft Corporation, in various capacities, including roles managing corporate strategy, sales, product marketing and segment focused teams in North America and Latin America. Mr. Taylor has served on the board of Jamf Holding Corp. (NASDAQ: JAMF) since 2017 and Ping Identity Holding Corp. (NYSE: PING) since November 2020. Mr. Taylor attended George Mason University.
Ms. DeFlorio was Managing Director, Deutsche Bank AG Retail/Consumer Sector Investment Banking Coverage from 2007 to 2013. While at Deutsche Bank, Ms. DeFlorio covered a range of mid- to large-cap retail clients. From 2002 to 2007, Ms. DeFlorio was an Executive Director in the Investment Banking Consumer and Retail Group at UBS Investment Bank. Ms. DeFlorio has served on the board of SITE Centers Corp. (NYSE: SITC) since 2017, where she is Chair of the Audit Committee and a member of the Compensation and Pricing Committees. Ms. DeFlorio served as a Director of Perry Ellis International from 2014 to 2018. Ms. DeFlorio is a member of the Board of Trustees and Chairman of the Audit and Risk Committee at The New School University in New York City. She also serves on the Boards of Directors for The Parsons School of Design, and the Museum at Fashion Institute of Technology. Ms. DeFlorio is a graduate of the University of Notre Dame and Harvard Business School.
On October 14, 2021, the Board of Directors (the “Board”) of X4 Pharmaceuticals, Inc. (the “Company”) appointed Francoise de Craecker as a member of the Company’s Board, effective immediately. Ms. de Craecker will serve as a Class III director until the Company’s 2023 Annual Meeting of Stockholders and until such time as her successor is duly elected and qualified, or until her earlier death, resignation or removal.
Ms. de Craecker will also serve as a member of the Compensation Committee of the Board, replacing Alison Lawton, who will continue to serve on the Board.
Mr. Morrison has served public and private companies in the life sciences industry since 1980. He was a Partner with Ernst & Young LLP (EY) from 1996 to 2015, serving as its U.S. Life Sciences Leader from 2002 to 2015. During his tenure at EY, he worked on hundreds of public and private financings, M&A transactions, and corporate collaborations. Mr. Morrison retired from EY in December 2015 and now serves on the boards and chairs the Audit Committees of Audentes, Inc. (through its sale to Astellas in January 2020), Corvus Pharmaceuticals, Global Blood Therapeutics (GBT), IDEAYA Biosciences, and Vera Therapeutics. He also serves as a member of the Compensation Committee for GBT and Corvus and is a member of GBT’s Commercial Committee.
Mr. Morrison has also served as a director on several life sciences industry boards, including the Emerging Companies Section (ECS) board of the Biotechnology Innovation Organization (BIO), the Bay Area Biosciences Board (now the California Life Sciences Association, or CLSA), the Life Sciences Foundation, and the Biotechnology Institute. Mr. Morrison was awarded the CLSA Pantheon 2016 Life Sciences Leadership Award. Mr. Morrison holds a B.S. in Business Administration from the Haas School at the University of California, Berkeley.
Okapi Partners’ Bruce Goldfarb Joins the Know Who Drives Return Podcast
Affirm Holdings Inc (AFRM)
Jeremy Philips ( 6.8 yrs; 27.9% TSR)
Aprea Therapeutics Inc (APRE)
Johan Christenson ( 5.8 yrs; -51.9% TSR)
Autozone Inc (AZO)
Michael M Calbert ( 2.6 yrs; 21.4% TSR)
Banc Of California Inc (BANC)
Barbara Fallon-Walsh ( 3.1 yrs; .7% TSR)
Capstead Mortgage Corp (CMO) (merger)
Michelle P Goolsby ( 9.3 yrs; 1.6% TSR)
Phillip A Reinsch ( 5.3 yrs; 1.4% TSR)
Jack Biegler ( 9.1 yrs; 1.2% TSR)
Patsy Joseph Augustine ( 1.2 yrs; 24.9% TSR)
Christopher W Mahowald ( 8.5% TSR)
Michael G Oneil ( 4.7% TSR)
Mark S Whiting ( 5.0% TSR)
Gary Keiser ( 4.7% TSR)
Cornerstone OnDemand Inc (CSOD) (merger)
Philip Seth Saunders ( 1.3 yrs; 33.1% TSR)
Dean E Carter ( 4.4 yrs; 9.8% TSR)
Felicia Alvaro ( .8 yrs; 42.4% TSR)
Joseph Osnoss ( 3.9 yrs; 9.6% TSR)
Nancy A Altobello ( .8 yrs; 42.4% TSR)
Adam L Miller ( 22.4 yrs; 11.3% TSR)
Richard M Haddrill ( 3.6 yrs; 10.3% TSR)
Robert N Cavanaugh ( 6.5 yrs; 10.4% TSR)
Sara Martinez Tucker ( .3 yrs; )
Steffan Tomlinson ( 4.4 yrs; 9.8% TSR)
Cullinan Oncology Inc (CGEM)
Owen Hughes ( .3 yrs; )
Delek Logistics Partners LP (DKL)
Francis C D'Andrea ( 6.3 yrs; 12.0% TSR)
El Pollo Loco Holdings Inc (LOCO)
Bernard Acoca ( 3.6 yrs; 16.0% TSR)
Kala Pharmaceuticals Inc (KALA)
Rajeev M Shah ( 6.3 yrs; -38.1% TSR)
Mge Energy Inc (MGEE)
Frank C Hastings ( 22.8 yrs; 11.2% TSR)
NeuroPace Inc (NPCE)
Evan Norton ( 1.3 yrs; -58.2% TSR)
Precision Biosciences Inc (DTIL)
Matthew R Kane ( 15.8 yrs; -16.5% TSR)
Rackspace Technology Inc (RXT)
Jean Brian Del St ( 3.9 yrs; -15.7% TSR)
Social Capital Hedosophia Holdings Corp IV (IPOD)
Nirav N Tolia ( 1.0 yrs; -10.0% TSR)
Sypris Solutions Inc (SYPR)
Sidney Rca Petersen ( 24.8 yrs; -3.6% TSR)
Toll Brothers Inc (TOL)
Richard J Braemer ( 35.5 yrs; 9.7% TSR)
Have someone that would like this post? Share it.
About Boardroom Alpha
Boardroom Alpha provides ratings, analytics, and context on US public company directors, CEOs, and CFOs. Learn more at www.boardroomalpha.com.